1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D863230D004A26A5002586180035E398
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-launching-new-biopharma-products-competitive-markets-preparing-market-constituents-understanding-efficacy-safety-dimensions?opendocument
18
19opendocument
203.232.96.22
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Launching New Biopharma Products in Competitive Markets: Preparing Market Constituents and Understanding Efficacy and Safety Dimensions

ID: 5648


Features:

16 Info Graphics

13 Data Graphics

215+ Metrics

2 Narratives


Pages/Slides: 37


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Launching New Biopharma Products in Competitive Markets: Preparing Market Constituents and Understanding Efficacy and Safety Dimensions”

STUDY OVERVIEW

With many promising therapies in development across multiple therapeutic areas, the biopharmaceutical launch paradigm is getting increasingly crowded. While new innovations often target previously underserved patient populations, a great portion of the industry pipeline is filled with assets targeting indications that are increasingly competitive.

Launching a new biopharma product successfully in such a competitive and complex environment requires an effective strategy that successfully leverages advantages and a tactical execution that averts pitfalls.

Best Practices, LLC undertook this benchmarking research to help biopharma leaders avert launch risks and capitalize on key launch strengths across a number of dimensions and stakeholders.

This study captures benchmarks and insights around launch success factors, positioning and differentiation factors, launch resource allocation, efficacy and safety dimensions, risk factors, and common launch pitfalls.

KEY TOPICS

  • Top success factors observed from launch leaders
  • Current and future risks for launch
  • The relative value of positioning and differentiation dimensions
  • Launch resource allocation
  • The most common failure points with leveraging efficacy and safety

KEY METRICS
  • Rate how much more effective (in points better) than a leading treatment does a new product now need to be to win physician trial and payer support in a therapeutic area with existing treatments
  • What are the top pitfalls you’ve observed and seek to avoid regarding establishing a new product’s efficacy and safety upon entering a competitive marketplace?
  • Rate the importance of various safety dimensions in encouraging physicians to try a new product that enters a competitive market
  • What investment levels - relative to the existing competitive landscape - are required for a new product to successfully enter a crowded marketplace?
  • Based on your most recent market entry experience, what was the resource allocation your company gave for engagement & education activities targeting key stakeholder groups during the Phase III to Launch period?
  • Rate the importance of educating and winning support from each market constituency in order to (1) Enter market, (2) Win Share, and (3) Grow Market
  • Estimate the current and future risk level of each internal pitfalls - market shaping and physician - that can derail a new product coming into a crowded market

SAMPLE KEY FINDINGS
  • Most Valuable Efficacy Traits:

    Superior competitive efficacy, halting disease progression, and supporting unmet needs are the most valuable efficacy traits for influencing the market at launch.


METHODOLOGY

Best Practices, LLC engaged 31 launch leaders from 27 companies in this research through a benchmarking survey instrument and interviews.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Manufacturing; Consumer Products; Health Care


Companies Profiled:
Adamas Pharmaceuticals; Alkermes; Allergan; Alnylam Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; BSN medical; Dicerna Pharmaceuticals; EMD Serono; F1 Oncology; Incyte; Lexicon Pharmaceuticals; Mallinckrodt; Medexus Pharmaceuticals; Novartis; PanTheryx; Inc.; Pfizer; Regeneron; Sandoz; Santhera Pharmaceuticals; Servier; Shire; Sunovion; Syros Pharmaceuticals; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.